^
Association details:
| Biomarker: | KRAS G12D |
|---|---|
| Cancer: | Pancreatic Cancer |
| Drug: | KS-58 (KRAS G12D inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Generation of KS-58 as the first K-Ras(G12D)-inhibitory peptide presenting anti-cancer activity in vivo
Published date:
12/10/2020
Excerpt:
KS-58 selectively binds to K-Ras(G12D) and suppresses the in vitro proliferation of the human lung cancer cell line A427 and the human pancreatic cancer cell line PANC-1, both of which express K-Ras(G12D). Moreover, KS-58 exhibits anti-cancer activity when given as an intravenous injection to mice with subcutaneous or orthotropic PANC-1 cell xenografts. The anti-cancer activity is further improved by combination with gemcitabine…KS-58 is an attractive lead molecule for the development of novel cancer drugs that target K-Ras(G12D).
Secondary therapy:
gemcitabine
DOI:
10.1038/s41598-020-78712-5
